U.S. Markets closed

GTx shares should be bought on weakness, says Wedbush

After an article which criticized data from a Phase II trial of GTx's Enobosarm caused the company's stock to plummet yesterday, Wedbush believes that the article was inaccurate and its conclusions were unfounded. The firm expects the treatment to meet its primary endpoints in Phase III studies. It reiterates a $9 price target and Outperform rating on the stock.